Phase 2 clinical trial results of the Medigen Vaccine Biologics Corp’s COVID-19 vaccine on Wednesday were published on the Web site of <i>The Lancet: Respiratory Medicine</i>, in an early preview before publication.
The study paves the way for other nations to issue emergency use authorizations or produce the Medigen vaccine, given <i>The Lancet’s</i> credibility as a highly respected medical journal with a rigorous peer-review process, Medigen’s international affairs director Lien Chia-en (連加恩) said.
Lien said that the study is important as it proposes methods for converting international units for efficacy comparisons.
The methods have been used for correlating the efficacy of hepatitis B